Product Description
HIPK1 (Homeodomain-interacting protein kinase 1), also known as Myak (myocardial kinase), is a member of the serine/threonine protein kinase family that plays a pivotal role in transcription regulation, cell proliferation, apoptosis, DNA damage response, and cellular stress signaling. HIPK1 is activated by autophosphorylation and interacts with homeodomain-containing transcription factors, p53, and other co-regulators, leading to downstream modulation of signaling pathways including p53-mediated apoptosis, JNK, TGF-β/Smad, and NF-κB. Beyond its role in normal development and tissue homeostasis, dysregulation of HIPK1 signaling—through overexpression, gene amplification, or altered kinase activity—is closely associated with various cancers (including breast cancer, prostate cancer, colorectal cancer, and glioblastoma), fibrosis, neurodegenerative diseases, and inflammatory disorders, making it a potential target for cancer therapy and drug discovery.
Screeningbio’s HIPK1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying HIPK1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: HIPK1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the HIPK1 kinase.
Data